Postoperative PainNCT07479069
Erector Spinae Plane Block for Pain Control After Open Abdominal Surgery
A study testing Bilateral Erector Spinae Plane (ESP) Block and Standard Postoperative Analgesia in people with Postoperative Pain and Open Abdominal Surgery, run by Fatima Memorial Hospital at 1 site in Pakistan.
Trial summary
his randomized controlled trial aims to evaluate the efficacy of the bilateral erector spinae plane (ESP) block in reducing postoperative opioid consumption in patients undergoing open abdominal surgeries under general anesthesia Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Postoperative Pain, Open Abdominal Surgery
- What is being tested?
- Bilateral Erector Spinae Plane (ESP) Block and Standard Postoperative Analgesia
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Oct 2025to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- American Society of Anesthesiology (ASA) stage I-II.
- Scheduled for abdominal surgery due to any indication.
Who cannot join
- History of Diabetes
- History of neuropathic diseases
- History of gastrointestinal bleeding, peptic ulcer, or inflammatory bowel disease
- History of long-term nonsteroidal anti-inflammatory
- History of chronic opioid analgesic use
- History of severe hepatic or renal failure
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Department of Anesthesia, Fatima Memorial Hospital
Lahore, Punjab Province, 54000
About this study
Official title: Effect of Bilateral Erector Spinae Plane Block on Postoperative Opioid Consumption in Open Abdominal Surgeries Under General Anaesthesia
his randomized controlled trial aims to evaluate the efficacy of the bilateral erector spinae plane (ESP) block in reducing postoperative opioid consumption in patients undergoing open abdominal surgeries under general anesthesia
Read the detailed description
Patients undergoing abdominal surgeries experience severe postoperative pain. Conventional pain management methods, including opiates, may pose significant side effects. This study addresses the imperative need for optimizing postoperative pain management by systematically investigating the analgesic effects and complications associated with the bilateral ESP block. The study involves 46 patients allocated into two groups using a lottery method: a control group receiving standard pain control treatment, and an erector spinae block group receiving a bilateral ESP block in addition to standard pain control treatment. Pain intensity will be evaluated using a visual analogue scale (VAS) at 4, 8, 12, and 24 hours after the operation.
- Conditions
- Postoperative Pain, Open Abdominal Surgery
- Being tested
- Bilateral Erector Spinae Plane (ESP) Block, Standard Postoperative Analgesia
- Keywords
- Erector Spinae Block
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bilateral Erector Spinae Plane (ESP) BlockProcedure or surgery
Administered after the induction of general anesthesia and before the surgical incision. Local anesthetic (0.25% ropivacaine or 0.25% bupivacaine) will be injected for a total of 20-40 mL
Standard Postoperative AnalgesiaDrug
Patients receive 1000 mg of IV paracetamol every 6 hours postoperatively. If a patient experiences a Visual Analogue Score (VAS) of more than five at any time, they receive rescue analgesia in the form of nalbuphine 4mg
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Active comparator | Patients receiving standard pain control treatment. Postoperatively, patients receive 1000 mg of IV paracetamol every 6 hours. If a patient reports a Visual Analogue Score (VAS) exceeding five, they will receive rescue analgesia consisting of nalbuphine 4mg Receives: Drug: Standard Postoperative Analgesia |
| Erector Spinae Block Group | Experimental | Patients receiving bilateral ESP block in addition to standard pain control treatment Receives: Procedure: Bilateral Erector Spinae Plane (ESP) Block; Drug: Standard Postoperative Analgesia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Opioid Consumption
Assessed by the percentage of patients requiring rescue opioid analgesia. The need for rescue analgesia is determined by a Visual Analogue Score (VAS) greater than five
Measured: Within the first 24 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2026
- Study start1 Oct 2025
- Primary completion31 Mar 2026 (estimated)
- Study completion31 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fatima Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fatima Majeed, Fatima Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07479069
- Sponsor's protocol ID
- FMH-15/12/2025-IRB-1840
- Status last verified
- Mar 2026
- First submitted
- 13 Mar 2026
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Bilateral Erector Spinae Plane Block on Postoperative Opioid Consumption in Open Abdominal Surgeries Under General Anaesthesia
- ClinicalTrials.gov ID
- NCT07479069
- Acronym / sponsor ID
- FMH-15/12/2025-IRB-1840
- Conditions
- Postoperative Pain, Open Abdominal Surgery
- Keywords
- Erector Spinae Block
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 46 participants (actual)
- Lead sponsor
- Fatima Memorial HospitalUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 31 Mar 2026 (estimated)
- Study completion
- 31 Mar 2026 (estimated)
- First posted
- 18 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
his randomized controlled trial aims to evaluate the efficacy of the bilateral erector spinae plane (ESP) block in reducing postoperative opioid consumption in patients undergoing open abdominal surgeries under general anesthesia
Detailed description
Patients undergoing abdominal surgeries experience severe postoperative pain. Conventional pain management methods, including opiates, may pose significant side effects. This study addresses the imperative need for optimizing postoperative pain management by systematically investigating the analgesic effects and complications associated with the bilateral ESP block. The study involves 46 patients allocated into two groups using a lottery method: a control group receiving standard pain control treatment, and an erector spinae block group receiving a bilateral ESP block in addition to standard pain control treatment. Pain intensity will be evaluated using a visual analogue scale (VAS) at 4, 8, 12, and 24 hours after the operation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Group | Active comparator | Drug: Standard Postoperative AnalgesiaPatients receiving standard pain control treatment. Postoperatively, patients receive 1000 mg of IV paracetamol every 6 hours. If a patient reports a Visual Analogue Score (VAS) exceeding five, they will receive rescue analgesia consisting of nalbuphine 4mg |
| Erector Spinae Block Group | Experimental | Procedure: Bilateral Erector Spinae Plane (ESP) Block, Drug: Standard Postoperative AnalgesiaPatients receiving bilateral ESP block in addition to standard pain control treatment |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- American Society of Anesthesiology (ASA) stage I-II.
- Scheduled for abdominal surgery due to any indication.
Key exclusion criteria (6 listed)
- History of Diabetes
- History of neuropathic diseases
- History of gastrointestinal bleeding, peptic ulcer, or inflammatory bowel disease
- History of long-term nonsteroidal anti-inflammatory
- History of chronic opioid analgesic use
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bilateral Erector Spinae Plane (ESP) BlockAdministered after the induction of general anesthesia and before the surgical incision. Local anesthetic (0.25% ropivacaine or 0.25% bupivacaine) will be injected for a total of 20-40 mL | Procedure or surgery | Erector Spinae Block Group |
| Standard Postoperative AnalgesiaPatients receive 1000 mg of IV paracetamol every 6 hours postoperatively. If a patient experiences a Visual Analogue Score (VAS) of more than five at any time, they receive rescue analgesia in the form of nalbuphine 4mg | Drug | Control Group, Erector Spinae Block Group |
Primary outcome
Postoperative Opioid Consumption
Time frame: Within the first 24 hours after surgery
Assessed by the percentage of patients requiring rescue opioid analgesia. The need for rescue analgesia is determined by a Visual Analogue Score (VAS) greater than five
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain
Not yet recruiting
PRP-Assisted Regenerative Endodontics Versus Conventional Root Canal Treatment in Mature Necrotic Teeth
Pulp Necrosis, Apical Periodontitis
Not yet recruiting
Magnesium Sulphate as an Adjuvant in Combined Costoclavicular Block and Suprascapular Block Versus Interscalene Block for Ambulatory Shoulder Arthroscopy
Postoperative Pain, Shoulder Arthroscopy
Not yet recruiting
Nerve Block of the Vastus Medialis and Anterior Obturator Branch in Anterior Cruciate Ligament Reconstruction With DIDT Graft
Anterior Cruciate Ligament (ACL) Reconstruction Surgery
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
Not yet recruitingPhase 3
Submucosal Cryotherapy and Anti-inflammatory Drugs for Postoperative Pain Following Root Canal Treatment in Maxillary Molars
Pulpitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bilateral Erector Spinae Plane (ESP) Block and Standard Postoperative Analgesia in people with Postoperative Pain and Open Abdominal Surgery, run by Fatima Memorial Hospital at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Opioid Consumption (time frame: Within the first 24 hours after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.